Clinical Trial Update: A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy [Phase 3]

View source ↗

Summary

Relmada Therapeutics has withdrawn its Phase 3 trial of NDV-01 administered intravesically for BCG-unresponsive non-muscle invasive bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• NDV-01

Snippet

Sponsor: Relmada Therapeutics, Inc. | Conditions: Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Status: WITHDRAWN